Antiviral nucleoside analogues represent a pivotal class of compounds that mimic physiological nucleosides and are enzymatically incorporated into viral genomes, thereby inhibiting viral polymerases ...

NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to ...

Antibiotic resistant bacteria are a threat to human lives, and yet the development of new drugs to treat bacterial infections is slow. A group of proven drugs used in cancer treatment for decades ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...

Researchers from Hokkaido University (Japan) and colleagues have identified 2-thiouridine (s2U) as a broad-spectrum antiviral ribonucleoside analogue, by phenotypic screening of a library of 753 ...